Bi-PegLyte

ApprovedSmall molecule

UUniversity of Manitoba

Bi-PegLyte is one of 37 small molecule programs targeting Ulcerative Colitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisActive, not recruiting

Ulcerative ColitisApproved

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Tremfya

Johnson & Johnson

Phase 3

2 2

Mesalazine

Ferring

Phase 3

17 3

CP-690,550

Pfizer

Phase 3

2 4

PTM SEMA

Gilead

Phase 3

1 5

JNJ-42756493

RPC1063

2 7

Bi-PegLyte

UUniversity of Manitoba

Approved

1 8

Etrolizumab

Roche

Phase 3

7 9

Simponi

Johnson & Johnson

Preclinical

15 10

CT-P13 SC (infliximab)

CCelltrion

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.

Recruiting·UUniversity of Manitoba·Phase 4·NCT06298461·418 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bi-PegLyte. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bi-PegLyte compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bi-PegLyte. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Manitoba company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Manitoba

Bi-PegLyte

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News